Drawing lines in the sand: The growing threat of obesity in type 1 diabetes

Table 1 Advantages and disadvantages of use of new glucose-lowering agents in individuals with type 1 diabetes mellitus

Drug class	Advantages	Disadvantages
GLP-1 RA	Reduction in HbA1c, insulin dose, and body weight/cardioprotective effects/improvement in liver steatosis	GI side effects/increase in ketosis rates/increased cost for health care systems
SGLT2i	Reduction in HbA1c, insulin dose, body weight, and glycemic variability/cardio-renal protective effects	Increased risk of DKA/minimal weight-lowering effects/increased cost for health care systems
Tirzepatide	Reduction in HbA1c, insulin dose, and body weight/improvement in liver steatosis	Very limited data in T1DM/increased cost for health care systems

T1DM: Type 1 diabetes mellitus; HbA1c: Glycated hemoglobin; DKA: Diabetic ketoacidosis; GI: Gastrointestinal; GLP-1: Glucagon-like peptide 1 receptor agonists; SGLT2i: Sodium-glucose cotransporter 2 inhibitors.